Clinical review report. AbobotulinumtoxinA (Dysport therapeutic) : (Ipsen Biopharmaceuticals Canada, Inc.).

Clinical review report. (Ipsen Biopharmaceuticals Canada, Inc.). AbobotulinumtoxinA (Dysport therapeutic) :

Show other versions (7)

The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the treatment of upper limb spasticity (ULS) in adults.

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK534668/
Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Muscle Spasticity > drug therapy.
Upper Extremity > physiopathology.
Botulinum Toxins, Type A > therapeutic use.
Botulinum Toxins, Type A > adverse effects.
Canada.
Systematic Review.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK534668/
Full text

Similar Items